Skip to main content
. 2022 Aug 13;14(8):1690. doi: 10.3390/pharmaceutics14081690

Figure 3.

Figure 3

Dose-dependent IL-2 production by DN32.D3 mouse NKT cell hybridoma activated in vitro by PLGA nanovaccine formulations generated at the (A) lab scale and (B) industrial scale. Data obtained for particles containing peptide 1, peptide 2 and peptide 3 are represented in blue, purple and grey, respectively. Placebo particles, free soluble IMM60 and negative control are depicted in green, yellow and black, respectively.